key: cord-0657123-h5lnfl5d
authors: Zhou, Zhengqing; Zhao, Zhiheng; Shi, Shuyu; Wu, Jianghua; Li, Dianjie; Li, Jianwei; Zhang, Jingpeng; Gui, Ke; Zhang, Yu; Mei, Heng; Hu, Yu; Ouyang, Qi; Li, Fangting
title: Model-based cellular kinetic analysis of SARS-CoV-2 infection: different immune response modes and treatment strategies
date: 2021-01-12
journal: nan
DOI: nan
sha: 1340a1cd0c032eb5e6f3c6889fef45237c3e9c69
doc_id: 657123
cord_uid: h5lnfl5d

Increasing number in global COVID-19 cases demands for mathematical model to analyze the interaction between the virus dynamics and the response of innate and adaptive immunity. Here, based on the assumption of a weak and delayed response of the innate and adaptive immunity in SARS-CoV-2 infection, we constructed a mathematical model to describe the dynamic processes of immune system. Integrating theoretical results with clinical COVID-19 patients' data, we classified the COVID-19 development processes into three typical modes of immune responses, correlated with the clinical classification of mild&moderate, severe and critical patients. We found that the immune efficacy (the ability of host to clear virus and kill infected cells) and the lymphocyte supply (the abundance and pool of na"ive T and B cell) play important roles in the dynamic process and determine the clinical outcome, especially for the severe and critical patients. Furthermore, we put forward possible treatment strategies for the three typical modes of immune response. We hope our results can help to understand the dynamical mechanism of the immune response against SARS-CoV-2 infection, and to be useful for the treatment strategies and vaccine design.

Coronavirus disease 2019 caused by the coronavirus SARS-CoV-2 has spread globally, having a huge impact on global politics, economy and society.

Compared to other viral infectious diseases, such as influenza, severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and acquired immune deficiency syndrome (AIDS), COVID-19 exhibits multiscale different characteristics.

Epidemiologically, COVID-19 has a relatively longer incubation period (~5.8 days) with a number of asymptomatic patients, which intensifies the difficulty of management and prevention (1). For the within-host viral infection, about 80% COVID-19 patients exhibit mild symptoms and recover within 3~4 weeks after regular treatments (2) . The severe and critical COVID-19 patients (~20%) are related to lymphopenia, high neutrophil counts and cytokine release syndrome (CRS) or cytokine storm, characterized by elevated inflammatory cytokines levels like IL-6. CRS and succeeding comorbidities usually cause bad clinical outcome and even death, although the overall intensity of the cytokine storm in COVID-19 patients is milder than SARS patients (3) .

More studies and evidences show that the SARS-CoV-2 virus, compared to SARS-CoV and MERS-CoV, in the early infection period tends to induce less effective antiviral innate immune responses with a delayed or lower type-I interferon (IFN) response and lower HLA-II expression level (4, 5) . Furthermore, marked lymphopenia and impaired humoral immunity with the loss of germinal centers (6) suggest that the weak adaptive immune response could contribute to damped clearance of virus and thus chronic infection.

Though the knowledge and clinical data of COVID-19 is increasing, a systemic view of immunologic response in SARS-CoV-2 infection remains necessary. Due to the variance in immune status and response dynamic processes among patients, it is hard to make up an effective therapeutic schedule, for example, the effects of remdesivir, IFN-γ and antibodies remain controversial (7) (8) (9) (10) (11) (12) (13) .

Here, we investigated the immune response against SARS-CoV-2 infection by analyzing the longitudinal hemogram data of 194 patients from Wuhan Union Hospital 3 / 18 and also by mathematical modeling the within-host immune dynamics. We constructed within-host virus-immune interaction network, together with a mathematical model depicting the dynamic processes and the response of the innate immunity and adaptive immunity against SARS-CoV-2 infection. We simulated and classified the different modes of patient's immune responses, which correspond to the longitudinal data of COVID-19 patients, and we propose the possible treatment strategies to improve the immune status of COVID-19 patients.

The human immune system is a complex defense system involving dozens of different cell types and hundreds of interacting molecular pathways, protecting human body from dangerous pathogens. A mathematical model, which describes the complex interactions in immune system and the demographic differences in patient's health status, should help us to understand the underlying immune response, to classify the patients based on their immune response processes, and provide possible definitive treatment strategies.

We analyzed 194 COVID-19 patients' longitudinal data from Union Hospital of Tongji Medical College in Huazhong University of Science and Technology (Wuhan, P. R. China), including the hemogram, the serum cytokine profile and treatments at different time points, as well as their clinical classification and outcome. We found that among mild, severe and critical COVID-19 patients, the time sequences of counts of white blood cell, neutrophil and lymphocyte, together with IL-6 levels in peripheral blood behave significant different, indicating the severity of patients (Fig. 2B) . In critical patients, the elevated neutrophil counts and myeloid-derived suppressor cell (MDSC) fraction are significantly greater than the mild and severe patients, which could be accredited to the chronic viral and bacterial co-infection (Fig. S5B ).

Based on the recent evidences and clinical data about COVID-19, we put forward a possible immune mechanism during SARS-CoV-2 infection: a slow innate immune response in the early infection stage leading to extensive tissue damage and inflammation, and a weak adaptive immune response in later stage resulting in the chronic infection and bad clinical outcome.

We simplified both innate and adaptive immune response processes within-host caused by the SARS-CoV-2 infection, and constructed a virus-immune interaction network with the viral infection module, innate immunity, cellular immunity, humoral immunity, and immunosuppression modules (Fig. 1) the unit of cytokines is pg/mL, and the unit of antibodies is μg/mL.

In the viral infection module, we have the following equations to depict how the SARS-CoV-2 virus infects the lung epithelial cells.

The viral dynamics is described in Eq.1. The virion particles are produced from infected cells at the rate of

where γ stands for a conversion factor between particle count and extracellular particle number density, N1 is the burst size of SARS- When the naïve CD8+T cells meet and interact with antigen-loaded APCs in the lymph nodes, they are activated, proliferate and differentiate to CTL, then move to the lung area to fight against the virus. We use a logistic term to describe the homeostasis of naïve CD8+ T cell supply with capacity KCD8 and growth rate rCD8, kCTL represents the activation rate to CTL from the naïve CD8+ T cell by APC interaction. Thus, we wrote the dynamics of naïve CD8+T cell as:

Steady state solution gives out

. We define the host supply ability of naïve CD8+T cell as

indicates the ability of CD8+ T cell supply to produce more CTL. If 

Demographically, the immune system's capability and response vary individually, susceptible to age, fitness and gender differences (14, 15) . In Fig. 2A , we adopted Latin hypercube sampling method (16) Fig. 2C and Fig. 2D .

In comparison to mode 2, mode 3 is more likely to appear in older patients with underlying diseases, including but not limited to hypertension and diabetes mellitus, for their fragile immune systems. This view is also supported by recent study on the association between adaptive immunity and age (18) . In addition to these, in mode 3, Bacterial co-infection is tested positive in more than 50% of the deceased patients (2, 25) , which we also found clinically. We simulated the course of disease with bacterial co-infection arising from mode 2 and 3, and denoted them as mode 2*, mode 

We summarized our results in flowchart in Fig. 5 , as a reference for an ideal procedure in treating COVID-19 patients. 

The immune system is a complex defense system that protects us from the pathogens, quantitative clinical data has made a significant contribution to understand the dynamics of these viruses and the drug treatment strategy (26) (27) (28) (29) (30) .

Since 2019, the ongoing of COVID-19 pandemic has sickened millions and killed more than 1 million people worldwide. There is still a lack of reliable effective treatment strategies toward the different immune status in patients. In this study, we constructed a mathematical model to describe the dynamic response of immune system. We classified the COVID-19 development processes into three typical modes of immune responses, and put forward effective treatment strategies for relevant immune response processes.

In this work, we only focus on the immune response, and ignore other clinical symptoms such as multiple system and organ failure and pathological damage of other organs. We In our recent unpublished work, we are investigating more types of immune cells including the memory T and B cells, the bacteria infection and MDSC, together with the recirculation among blood, lung, lymph node, spleen and bone marrow. In addition, we hope our work can help to classify the patients clinically by their early period hemograms and cytokine profiles, and to choose effective treatments based on their dynamic immune status. Furthermore, we hope that our approach can be adapted to other kinds of viral and bacterial infections, and can be applied to describe and predict the cytokine storm on CAR-T immune treatment (31, 32) .

In summary, our work provides a quantitative framework about the complex interactions between virus infection and host immune response. More feedbacks with clinical treatment and data will help us to obtain the systemic and quantitative understanding of dynamics that immune system responds to the infection of SARS-Cov-2 virus.

Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

A single-cell atlas of the peripheral immune response in patients with severe COVID-19

Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19

Repurposed Antiviral Drugs for Covid-19 -Interim WHO Solidarity Trial Results

Remdesivir for the Treatment of Covid-19 -Final Report

Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies

Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury

Coronavirus breakthrough: dexamethasone is first drug shown to save lives

Demographic science aids in understanding the spread and fatality rates of COVID-19

Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis

Latin hypercube sampling and the propagation of uncertainty in analyses of complex systems

Characteristics of SARS-CoV-2 and COVID-19

Antigen-Specific Adaptive Immunity to SARS-CoV-2 in

Acute COVID-19 and Associations with Age and Disease Severity

Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia

Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review

Pathogenesis of IL-6 and potential therapeutic of IFN-γ in COVID-19

Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial

The Neutrophil-to-Lymphocyte Ratio Determines Clinical Efficacy of Corticosteroid Therapy in Patients with COVID-19

Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence

Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up

Virus dynamics and drug therapy

Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy

Viral dynamics in hepatitis B virus infection

Modelling viral and immune system dynamics

HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia